Advances in the pharmacological management of obsessive-compulsive disorder in the postpartum period

Vlasios Brakoulias; Kirupamani Viswasam; Alice Dwyer; Karen Hazell Raine; Vladan Starcevic

doi:10.1080/14656566.2019.1700229

Advances in the pharmacological management of obsessive-compulsive disorder in the postpartum period

Vlasios Brakoulias, Kirupamani Viswasam, Alice Dwyer, Karen Hazell Raine, Vladan Starcevic

Research output: Contribution to journal › Short survey › peer-review

2 Citations (Scopus)

Abstract

Introduction: Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by obsessions and compulsions. Obsessions are defined as intrusive, recurrent and distressing thoughts, images or impulses, whereas compulsions are defined as repetitive behaviors or mental acts. While there is an associated distress, and indeed oftentimes, the individual’s awareness that these behaviors are excessive and unreasonable, the individual continues to be disabled by an inability to cease their compulsions. The postpartum period may herald the onset of OCD or precipitate an exacerbation of the preexisting OCD symptoms. Common OCD symptom clusters occur in the postpartum period, with specific challenges associated with motherhood and lactation. Areas covered: This brief review aims to review the extent and nature of publications evaluating pharmacological treatment of OCD in the postpartum period. Expert opinion: Education and training should aim to improve the recognition and treatment of postpartum OCD. Due to the limited nature of studies, more research is required to assess the role of selective serotonin reuptake inhibitors in the postpartum period.

Original language	English
Pages (from-to)	163-165
Number of pages	3
Journal	Expert Opinion on Pharmacotherapy
Volume	21
Issue number	2
DOIs	https://doi.org/10.1080/14656566.2019.1700229
Publication status	Published - 22 Jan 2020
Externally published	Yes

Bibliographical note

Funding Information:
Vlasios Brakoulias is supported by grants from the Nepean Medical Research Foundation, from Pfizer Neuroscience, the University of Sydney and Western Sydney University. He is also an investigator on a Boehringer Ingelheim funded clinical trial and has received speaker fees from Lundbeck and Otsuka Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

Access to Document

10.1080/14656566.2019.1700229

Cite this

@article{a767adc6d6694d259a8d17e093211868,

title = "Advances in the pharmacological management of obsessive-compulsive disorder in the postpartum period",

abstract = "Introduction: Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by obsessions and compulsions. Obsessions are defined as intrusive, recurrent and distressing thoughts, images or impulses, whereas compulsions are defined as repetitive behaviors or mental acts. While there is an associated distress, and indeed oftentimes, the individual{\textquoteright}s awareness that these behaviors are excessive and unreasonable, the individual continues to be disabled by an inability to cease their compulsions. The postpartum period may herald the onset of OCD or precipitate an exacerbation of the preexisting OCD symptoms. Common OCD symptom clusters occur in the postpartum period, with specific challenges associated with motherhood and lactation. Areas covered: This brief review aims to review the extent and nature of publications evaluating pharmacological treatment of OCD in the postpartum period. Expert opinion: Education and training should aim to improve the recognition and treatment of postpartum OCD. Due to the limited nature of studies, more research is required to assess the role of selective serotonin reuptake inhibitors in the postpartum period.",

keywords = "breastfeeding, Obsessive-compulsive disorder, pharmacotherapy, postnatal, postpartum, selective serotonin re-uptake inhibitors",

author = "Vlasios Brakoulias and Kirupamani Viswasam and Alice Dwyer and Raine, {Karen Hazell} and Vladan Starcevic",

note = "Funding Information: Vlasios Brakoulias is supported by grants from the Nepean Medical Research Foundation, from Pfizer Neuroscience, the University of Sydney and Western Sydney University. He is also an investigator on a Boehringer Ingelheim funded clinical trial and has received speaker fees from Lundbeck and Otsuka Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

month = jan,

day = "22",

doi = "10.1080/14656566.2019.1700229",

language = "English",

volume = "21",

pages = "163--165",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Taylor & Francis",

number = "2",

}

TY - JOUR

T1 - Advances in the pharmacological management of obsessive-compulsive disorder in the postpartum period

AU - Brakoulias, Vlasios

AU - Viswasam, Kirupamani

AU - Dwyer, Alice

AU - Raine, Karen Hazell

AU - Starcevic, Vladan

N1 - Funding Information: Vlasios Brakoulias is supported by grants from the Nepean Medical Research Foundation, from Pfizer Neuroscience, the University of Sydney and Western Sydney University. He is also an investigator on a Boehringer Ingelheim funded clinical trial and has received speaker fees from Lundbeck and Otsuka Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2020/1/22

Y1 - 2020/1/22

N2 - Introduction: Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by obsessions and compulsions. Obsessions are defined as intrusive, recurrent and distressing thoughts, images or impulses, whereas compulsions are defined as repetitive behaviors or mental acts. While there is an associated distress, and indeed oftentimes, the individual’s awareness that these behaviors are excessive and unreasonable, the individual continues to be disabled by an inability to cease their compulsions. The postpartum period may herald the onset of OCD or precipitate an exacerbation of the preexisting OCD symptoms. Common OCD symptom clusters occur in the postpartum period, with specific challenges associated with motherhood and lactation. Areas covered: This brief review aims to review the extent and nature of publications evaluating pharmacological treatment of OCD in the postpartum period. Expert opinion: Education and training should aim to improve the recognition and treatment of postpartum OCD. Due to the limited nature of studies, more research is required to assess the role of selective serotonin reuptake inhibitors in the postpartum period.

AB - Introduction: Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by obsessions and compulsions. Obsessions are defined as intrusive, recurrent and distressing thoughts, images or impulses, whereas compulsions are defined as repetitive behaviors or mental acts. While there is an associated distress, and indeed oftentimes, the individual’s awareness that these behaviors are excessive and unreasonable, the individual continues to be disabled by an inability to cease their compulsions. The postpartum period may herald the onset of OCD or precipitate an exacerbation of the preexisting OCD symptoms. Common OCD symptom clusters occur in the postpartum period, with specific challenges associated with motherhood and lactation. Areas covered: This brief review aims to review the extent and nature of publications evaluating pharmacological treatment of OCD in the postpartum period. Expert opinion: Education and training should aim to improve the recognition and treatment of postpartum OCD. Due to the limited nature of studies, more research is required to assess the role of selective serotonin reuptake inhibitors in the postpartum period.

KW - breastfeeding

KW - Obsessive-compulsive disorder

KW - pharmacotherapy

KW - postnatal

KW - postpartum

KW - selective serotonin re-uptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85078504784&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1700229

DO - 10.1080/14656566.2019.1700229

M3 - Short survey

C2 - 31893946

AN - SCOPUS:85078504784

SN - 1465-6566

VL - 21

SP - 163

EP - 165

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 2

ER -

Advances in the pharmacological management of obsessive-compulsive disorder in the postpartum period

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this